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Abstract
Background: Oral cancer is a major health problem worldwide. The 5-year survival rate ranges from 30-60%, and
has remained unchanged in the past few decades. This is mainly due to late diagnosis and high recurrence of the
disease. Of the patients who receive treatment, up to one third suffer from a recurrence or a second primary
tumor. It is apparent that one major cause of disease recurrence is clinically unrecognized field changes which
extend beyond the visible tumor boundary. We have previously developed an approach using fluorescence
visualization (FV) technology to improve the recognition of the field at risk surrounding a visible oral cancer that
needs to be removed and preliminary results have shown a significant reduction in recurrence rates.
Method/Design: This paper describes the study design of a randomized, multi-centre, double blind, controlled
surgical trial, the COOLS trial. Nine institutions across Canada will recruit a total of 400 patients with oral severe
dysplasia or carcinoma in situ (N = 160) and invasive squamous cell carcinoma (N = 240). Patients will be stratified
by participating institution and histology grade and randomized equally into FV-guided surgery (experimental arm)
or white light-guided surgery (control arm). The primary endpoint is a composite of recurrence at or 1 cm within
the previous surgery site with 1) the same or higher grade histology compared to the initial diagnosis (i.e., the
diagnosis used for randomization); or 2) further treatment due to the presence of severe dysplasia or higher
degree of change at follow-up. This is the first randomized, multi-centre trial to validate the effectiveness of the FV-
guided surgery.
Discussion: In this paper we described the strategies, novelty, and challenges of this unique trial involving a
surgical approach guided by the FV technology. The success of the trial requires training, coordination, and quality
assurance across multiple sites within Canada. The COOLS trial, an example of translational research, may result in
reduced recurrence rates following surgical treatment of early-stage oral cancer with significant impacts on survival,
morbidity, patients’ quality of life and the cost to the health care system.
Trial Registration: Clinicaltrials.gov NCT01039298
Background
Oral cancer is a major health problem worldwide,
accounting for 274,000 new cases and 145,000 deaths
annually [1]. Although it occurs at a site that is easily
accessible for examination it is often diagnosed at an
advanced stage, with 5-year survival rates ranging from
30-60%, depending on the global locale. Treatment of
early stage squamous cell carcinoma is an essential com-
ponent of effective oral cancer management; a recent
large (~190,000) randomized trial of a screening pro-
gram showed the mortality rate ratio between interven-
tion and control groups was 0.79 [95% CI 0.51 - 1.22]
[2]. However, even with treatment there are high rates
of second oral malignancies, with up to a third of these
patients suffering a recurrence or a second primary
[3,4]. There has been extensive research in the
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importance of examining the field surrounding oral can-
cers for risk assessment and management of this disease
[5-7]. Using molecular technology, it is becoming
increasingly apparent that genetically altered cells are
often widespread across the mucosa of patients with
oral cancer, extending into clinically and histologically
normal tissue, and that these cells can drive the process
of field cancerization. Recognizing this, surgeons try to
remove oral squamous cell carcinomas (SCC) with a sig-
nificant margin of surrounding normal-looking oral
mucosa. However, the occult disease varies in size and a
wealth of evidence suggests that it frequently extends
beyond the tumor clearance area [5-8]. This extension
may be responsible for the high rate of cancer recur-
rence at the primary site (10-30% of SCC cases) [9-11].
Taking margins that are too large can result in over-cut-
ting (causing severe cosmetic and functional morbidity)
and margins that are too small may leave cancerous tis-
sue behind, as evidenced by frequent positive surgical
margins and high local and regional recurrence - a fail-
ure of the ‘best practice’.
Our research team has developed an approach using
fluorescence visualization (FV) technology, which
improves the recognition of the field at risk surrounding
a visible oral cancer [12,13]. Our preliminary results
show that using FV to define the field at risk for surgi-
cal resection can result in a marked reduction in recur-
rence rates at 3 years (0/38 vs. 7/22) [14]. Our goal in
this study is to rigorously evaluate and validate the
effectiveness of FV-guided surgeries compared to white
light in a multicentre pan-Canadian randomized control
study.
Objective
The trial has 4 objectives. The primary objective is to
determine the effectiveness of FV-guided surgery in
reducing local recurrence after surgical excision of
severe dysplasia or cancer of the oral cavity. Secondary
objectives include 1) To collect molecular and phenoty-
pic evidence in margins to test if FV produces a shift in
surgical field, sparing normal tissue while catching high-
risk occult tissue; 2) To collect relative cost-effective evi-
dence of the two arms in both the cost per avoided
recurrence and the cost per quality-adjusted life years
gained; and 3) To develop a knowledge translation (KT)
strategy that will foster the dissemination of FV-guided
surgery across Canada and globally.
Methods/design
Study design
The COOLS trial is a multicentre, double blind, rando-
mized controlled study, comparing FV- guided surgery
(experimental arm) to conventional white light (WL)-
guided surgery (control arm). See Figure 1 for the
schema of the study.
This study has been approved by the human research
ethics committees at each of the participating institu-
tions. Any future amendments to the study protocol
will be submitted to each committee for approval. The
trial has been registered at Clinicaltrials.gov
(NCT01039298).
Sample size
A total of 400 subjects (240 invasive squamous cell car-
cinoma and 160 severe dysplasia or carcinoma in situ)
will be randomized from 9 centres across Canada (from
west to east): Vancouver, British Columbia; Calgary and
Edmonton, Alberta; Winnipeg, Manitoba; Toronto (Sun-
nybrook Hospital), London, and Ottawa, Ontario; Mon-
treal (McGill University Health Centre), Quebec;
Halifax, Nova Scotia.
Target population
The study is open to patients with high-grade preinva-
sive (severe dysplasia/carcinoma in situ) or invasive
squamous cell carcinoma (T1 or T2) of the oral cavity.
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Figure 1 Trial schema. A total of 400 subjects (240 invasive squamous cell carcinoma and 160 severe dysplasia or carcinoma in situ) will be
randomized equally into FV-guided surgery (experimental arm) or white light-guided surgery (control arm). The primary endpoint is a composite
of recurrence at or 1 cm within the previous surgery site with 1) the same or higher grade histology compared to the initial diagnosis (i.e., the
diagnosis used for randomization); or 2) further treatment due to the presence of severe dysplasia or higher degree of change at follow-up.
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Inclusion Criteria
Patients with disease localization at oral anatomical sites
that can be visualized using both white light and fluor-
escence visualization device (this includes ICD-10 site
codes: C02.0-C06.9); patients with a clinical diagnosis of
N0 or N1 as confirmed by CT scan, with the latter
undergoing neck dissection; or patients with resectable
locally recurrent disease diagnosed with severe dysplasia
or higher grade, provided that they are at least 6 months
post-treatment (this time frame will allow resolution of
artefacts produced by treatment that could impact on
tumor or lesion visualization).
Exclusion Criteria
Patients with concurrent non-oral malignancy diagnosed
within the past 3 years (patients with non-melanoma skin
cancer or lymphoma that lie outside of the head and neck
region are included); patients with evidence of distant
metastasis, as determined by CT and X-ray at the time of
recruitment; patients with illnesses that could preclude
standard diagnostic tests and post-surgery follow-up; and
patients with lesions located at the base of tongue (C01) or
tonsil (C09), as these sites are not readily assessable to FV.
All patients will provide written informed consent for
study participation.
Key steps
Patient recruitment
Site surgeons will identify potentially eligible patients
and briefly introduce the study to the patient (see key
steps in Figure 2). The local site coordinator will be
informed and will contact the patient to arrange an
appointment to discuss the study and for a pre-surgery
assessment. As part of that eligibility assessment, all
patients with squamous cell carcinoma will have a CT
scan from skull base to chest as a baseline to confirm
the clinical nodal status and the absence of the upper
alimentary and respiratory tract and lung metastasis or
second primary tumor. Upon verifying all the eligibility
criteria, the study coordinator will obtain informed con-
sent from the eligible and interested patients.
Pre-surgery assessment
Prior to the assessment, the site coordinator will assist the
patient to complete a set of study questionnaires covering
socio-demographic factors, risk factors, comorbidity and
family cancer history. Quality of life will be assessed with
the EQ-5D [15,16], the Functional Assessment of Cancer
Therapy Head and Neck Module (FACT-H&N)[17,18]
and the Speech Handicap Index, a specific tool for the
measurement of speech pathology. [19]
The lesion undergoing surgery will be assessed by a
trained FV Specialist (FVS) using both WL and FV. The
FVS will be either a dental specialist or a head & neck
surgeon who will not be performing the surgery for the
patient. With the assistance of the site coordinator, digi-
tal images will be obtained of the lesion under both
conditions and lesion size and location will be recorded
on the case report form (CRF). Both the images and the
CRF will be uploaded to the trial’s web-based database.
The FV assessment will be performed with an auto-
fluorescence imaging device, marketed as the VEL-
scope®, (LED Dental Inc., White Rock, British
Columbia, Canada), using protocols described in Poh
et al. [12] The examination is performed under reduced
room lighting and involves the inspection of the entire
oral mucosa in the same manner as the conventional
intraoral examination, with special attention to the
lesion site. Tissue that show a reduction in the normal
pale green, appearing as dark patches, will be categor-
ized as FV positive (FVpos). Lesions that retain the nor-
mal green autofluorescence under FV are classified as
FV negative (FVneg). Both WL and FV digital images of
the lesion will be recorded prior to randomization.
Intervention (Surgery)
At the time of surgery the operating surgeon will outline
the boundary of the clinically visible lesion under white
light. The FVS will take an image (Image 1); measure
its size; and record data on the surgical tracking sheet.
a. If this is a FV-guided surgery (experimental arm)
With the operating room (OR) lights off, the FVS will
use the VELscope Vx to examine the lesion and outline
the FV change using a green Sharpie pen. After the FV
positive boundary is outlined, images (Image 2) are
taken in the dark to demonstrate the distance between
FVL and clinical outline.
With the OR light back on, the FVS will measure the
distance from FV boundary to the clinical boundary in 4
directions, and record this on the surgical tracking
sheet. The site surgeon will outline a 10 mm surgical
boundary around the clinically visible tumor and FV
boundaries, whichever is wider. The FVS will take
images (Image 3) under both FV and WL and record if
there is any anatomical restriction for the placement of
the standardized surgical boundary.
b. If this is a WL- guided surgery (control arm) With
the light off, the FVS will use the VELscope VX to
examine the lesion and draw an outline on top of the
surgeon’s clinical boundary using a green Sharpie pen.
After this step, the FVS will take another set of images
(Image 2). In this case, the 2 outlines will be identical
and this will be recorded on the surgical tracking sheet.
The surgeon will outline a 10 mm surgical boundary
around the clinical/FV boundary. The FVS will take
images (Image 3) under both FV and WL and record if
there is any anatomical restriction for the placement of
the standardized surgical boundary.
The operating surgeon will remain outside the OR
while the FVS marks the boundaries. Although it is
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unlikely the surgeon will remain blinded once the two
markings are made, any deviation from the marked
boundary will be recorded to allow assessment of devia-
tion from the protocol.
Blood samples (5 ml in SST and 12 ml in EDTA
tubes) will be collected at this time prior to the surgery.
The tumor will then be resected and oriented using a
suture for the anterior or right orientation. This will be
indicated on the routine pathology requisition form to
help the SP to orient the resected tissue. The specimen
will be wrapped in a piece of cold saline gauze and kept
on ice during transfer to the Pathology Department for
processing.
The Site Pathologist (SP) will either use the tracking
sheet or a print-out of the digital image of the excised
tissue to record the tissue blocking. One-week after the
diagnosis has been determined all the H&E sections will be
sent to the Central Histology Review committee for histo-
logical review. If there is disagreement on the assessment
between the site pathologist and the review committee, a
teleconference will be arranged in order to discuss and
achieve consensus. The site coordinator will upload all
images, surgical and pathological CRFs and key informa-
tion from pathology reports into the study database.
Follow-up
All patients will return for follow-up examinations every
3 months for two years and then every 6 months for the
remainder of the study period. At each visit the entire
oral mucosa will be examined under WL, with surgery
sites photographed. The presence of lesions will be
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Figure 2 Flow chart of key steps and the involvement of key personnel in each steps and site coordinator’s role.
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noted on lesion tracking sheets along with lesion size
and location. Updated clinical information, digital
images and data fields from the quality of life question-
naires will be uploaded to the database by the SC.
Decision to biopsy will depend on the clinical judg-
ment of the surgeon, based on suspicion of a recurrence.
If there is no significant clinical change, a biopsy will be
taken at the surgery site at 2-year post surgery. A repeat
CT scan is warranted if there is clinical suspicion of
regional or distant diseases. If there is no clinical indica-
tion, Neck CT scan and a chest X-ray will be arranged
at 2-year post surgery follow-up.
Randomization
Stratified randomization will be employed. Two stratifi-
cation factors will be applied: 1) institution and 2) histo-
logical grade of the primary lesion (severe dysplasia and
carcinoma in situ or invasive squamous cell carcinoma).
A randomization program has been written specifically
for this trial (JJL). According to the information collected,
the central database manager under the supervision of the
study biostatistician (PMB) will perform the randomiza-
tion. Within each stratum, the minimization algorithm will
be used to achieve balanced randomization with respect to
other prognostic factors, including surgeon, gender, age,
smoking history, and lesion anatomical sites. [20]
The randomization will be done 1 - 2 days prior to
surgery. Only the FVS will be notified of the result. The
patient, research staff, operating surgeon, and the
pathologist are not aware of the assignment. The alloca-
tion list will be held by the study database manager; this
individual is not involved in patient care or recruitment.
The allocation will only be revealed in the event of an
emergency medical situation.
Outcome evaluation
Primary endpoint
A composite endpoint will be used for outcome evalua-
tion. The components are 1) local recurrence defined as
a recurrence at or within 1 cm of the previous surgery
site, with the same or higher grade histology compared to
the initial diagnosis or 2) further treatment due to the
presence of severe dysplasia or higher degree of change
at follow-up. This is consistent with the current practice
at all participating sites that only high-grade lesions (i.e.
≥ severe dysplasia) require further treatment. The end-
point will be evaluated and adjudicated by the Centre
Pathology Review Committee (chaired by KWB) of which
members are blinded to the treatment assignment.
Secondary endpoints
In addition to the primary endpoint, we are also inter-
ested in the following endpoints.
1. Failure of the ‘first pass’. A histologically-confirmed
positive margin for severe dysplasia or greater histologi-
cal change, either at the intraoperative or paraffin sam-
ple assessment, will count as failure of the ‘first pass’
margin (surgical failure). Should this happen, an addi-
tional strip of tissue will be taken during surgery or a
second surgery will be performed. For the latter case,
the second surgery will be done according to the
patient’s originally assigned surgical approach (i.e., WL-
or FV-guided).
2. Regional or distant metastasis: At any follow-up
time point, failure of regional or distant control, i.e.,
development of metastatic disease to regional lymph
nodes confirmed by fine needle aspiration, CT or MRI,
or subsequent pathology diagnosis.
3. Disease-specific survival: Patient’s death due to dis-
ease recurrence, including failure in local, regional and
distant control, is considered an event. Patients who die
of causes unrelated to their oral cancer or treatment of
their oral cancer are censored at the time of event.
Patients lost to follow-up are considered censored at the
last follow-up time.
Statistical design and analysis
The trial data will be analysed by the biostatistician
(PMB) who will be blinded to the treatment allocation
(masked as Treatment A or Treatment B) during the
study period.
Sample size
Assuming the survival curves follow exponential distri-
butions, a 25% failure rate at 3 years in the WL arm and
a hazard ratio of 0.5 (i.e. ~12.5% failure rate in the FV
arm), a 36-month accrual period, a minimum of 2 years
of follow-up, with an overall two-sided a = 0.05, a total
sample size of 350 patients is required to achieve at
least 80% power using the stratified log-rank test.
Assuming 10% of patients may be lost to follow-up we
will randomize 400 patients.
Two interim analyses for efficacy are planned (at one-
third and two-thirds of predicted outcomes) with a final
analysis at the end of Year 5. A Lan-Demets spending
function with O’ Brien-Fleming type stopping bound-
aries will be employed.
Monitoring
A Data Safety and Monitoring Board (DSMB) will meet
yearly to monitor accrual and adverse events. The
DSMB will also review the results of the interim ana-
lyses and provide a recommendation as to whether or
not the trial should be stopped early for efficacy. The
DSMB will be comprised of a medical oncologist, a head
& neck surgeon, and a biostatistician.
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Fidelity of the intervention
The COOLS trial examines the efficacy of using a
device. How to transfer the technique with uniformity
to the participating sites across Canada is the key to
success.
It will be necessary to establish uniform standard
operating procedures (SOPs) for all key activities; how-
ever, each site will have its own unique environment
and personnel. Prior to activation, each site will be vis-
ited with the delivery of study devices. During these vis-
its the multidisciplinary team of surgeons, pathologists,
project coordinators, and FVS at each site will be
trained in all study procedures. These site visits will also
provide a face-to-face opportunity to build strong rela-
tionships with site team members that should facilitate
problem solving throughout the study.
Along with the site visits, a comprehensive training
manual has been created and is made accessible to each
site through study’s web-based database. This training
manual includes study protocols, operation details for
each key step, how to complete and upload the scan-
nable CRFs, sections for clinicians/surgeons with an
atlas of clinical lesions in both WL and FV images and
instructions for the VELscope, VELscope Vx and cam-
era, sections for the pathologists with details in tissue
blocking and the definition of key fields in the pathology
synoptic report form. This manual will serve as a proto-
type that will be evaluated and fine-tuned throughout
the project for future knowledge translation. The study
website also includes a library of all study CRFs that can
be downloaded.
For clinical images and the use of VELscope, all FV
operators (FVS and SS) will need to pass a 2-step con-
trol process. Step 1: as part of the training process, two
sets of 8 images will be provided to the site surgeons
and FVS, as a first step in calibrating their judgment on
clinically visible tumor boundaries and FV positive (FV
loss) boundaries. The criteria for passing the step is that
both clinically visible tumor boundaries and FV bound-
aries need to be within ± 5 mm of those drawn by the
experienced FV operators from the British Columbia
(BC) site. Step 2 : to be certified, all FV operators
require hands-on experience in outlining the tumor and
FV boundaries on 2 real patients. The same criteria will
be used to assess this activity, with a requirement that
both clinically visible tumor and FV boundaries be
within ± 5 mm of those drawn by the experienced FV
operators from BC site. This time, the BC specialists
will draw on the images received from the study sites.
This can be used to review the entire operation from
new patient assessment to the completion of surgery
(see Key Steps above) to ensure the high-quality
operation.
After passing this 2-step control process, a site will be
ready to recruit the first patient to the study. The PI
(CFP) will review the first 10 patients from each site to
ensure the quality of images is maintained and that
mapping of clinical and fluorescence boundaries pro-
ceeds as per initial training and to provide suggestions
to the site team members for any problems experienced
during these activities. Subsequently, about 5% random
samples from each site will be selected from time to
time to check for the accuracy of boundary drawings.
This can also mitigate ‘margin creep’ over time.
One risk is the potential contamination of endpoint by
the surgeon, i.e., margin creep (expanding margins) in
the control arm. We are requiring that both the FV and
white light margins be justified just prior to surgery in
the operating room with the presence of both surgeon
and an independent party for FV assessment. In this
fashion, the surgical margin will be placed in a con-
sented and unbiased fashion. In order to keep the study
double blinded and avoid potential bias, the FVS will be
a different person from the SS. The periodic review of
sites by central management team will also mitigate this
problem.
Data quality
The acquisition of high quality data is key to the success
of any clinical trial. We have planned a systematic strat-
egy for control of data and image capture with a special
focus on ensuring that the involved processes are effi-
cient and of high quality. For clinical data, we use a set
of scannable teleforms. These forms can be scanned and
quickly uploaded from the participating sites to the cen-
tral database. The use of scannable forms will signifi-
cantly increase the efficiency of the knowledge capture
and avoid transcription errors during the data collection
process. The central database manager will review
uploaded CRFs for completeness and review any pro-
blems with the local site coordinators who will have
access to the uploaded forms through a user interface.
In order to maintain the high quality operation and
integrity of the study, the CPM will periodically perform
a random check of all processes of selected cases, with
at least 1 case from each site every 3 months. The data-
base will be programmed to alert the Centre and Site if
a patient is overdue for their scheduled follow-up
appointment. A monthly teleconference with site coordi-
nators and site PIs will share problems among sites. We
monitor the trial activity on a day-to-day basis and a
common email account has been set up to alert urgent
issues from the site. Any operational questions in the
project will be brought forward to the Steering Commit-
tee. All problems and solutions will be logged for future
reference.
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A major risk to the success of this project is patient
enrolment. This risk will be mitigated by requiring each
site to develop patient pipeline strategies. This is a mile-
stone driven project. With the consideration of allowing
sufficient start-up time for each site to build its infra-
structure, we project to recruit 400 patients over the
first 36 months of the trial starting date.
Discussion
The COOLS trial is a multicenter, phase III randomized
controlled trial comparing 2 surgery approaches, one
guided with a optical device (VELscope; experimental
arm) and one without (control arm), which is different
from the conventional drug trial. This is a large scale
pan Canadian study to validate an FDA- and Health
Canada-approved optical device to better define the sur-
gical margin. We acknowledge the support and the
shared vision from the Terry Fox Research Institute.
The uniqueness of this trial is multi-fold. Firstly, this
is the first-ever pan Canadian surgical study of such
calibre, involving 9 institutions across 6 provinces, more
than 70 health professionals, and 400 patients. The 9
institutions are drawn from academic centres with a
residency program and affiliated to provincial cancer
agencies, with patient populations of interest, linkages to
the dental system (referral pathway for patients), and
onsite pathology services. The catchment areas of these
participating sites cover over the locations from which
70% of oral cancer patients come from. Every year,
there are ~3,400 patients diagnosed with oral cancer in
Canada and ~60% are early stage oral cancer, which are
the target population of our trial. Hence, if the results
are validated, it can make enormous impact at the
patient level in increasing patients’ survival, morbidity,
and quality of life, at the institutional level in changing
the standard of care, and at the population level in
improving the cure rate and reducing costs to the health
system.
Secondly, this is an exceptional example of translational
research from bench to bedside, from discovery to clinical
implication. With the strong support of the ongoing Oral
Cancer Predictive Longitudinal (OCPL) Study, BC
researchers have built a strong foundation to lead this pro-
spective, multicenter study. The OCPL study is an NIH/
NIDCR-funded study which involves ~900 patients with
oral precancer and oral cancer that have been monitored
regularly since 1999 for progression/recurrence of disease.
The OCPL study has served as a pipeline for referral of
such patients to the trial in BC [21].
Thirdly, in order to change clinical practice we need
to ascertain clinical efficacy through assessment of local
recurrence at the clinical, histological and molecular
level, assess the impact on quality of life and cost effec-
tiveness, and construct a plan for KT. The molecular
goal will examine the margin to see if the tool can pro-
duces a shift in surgical field, sparing normal tissue
while catching high-risk occult tissue. The health eco-
nomics goal will collect relative cost-effective evidence
of the two treatments in both the cost per avoided
recurrence and the cost per quality-adjusted life years
gained and last but not the least, in the knowledge
translation (KT) goal, we plan to develop a KT strategy
that will facilitate rapid scale up of FV-guided surgery in
Canada and beyond. With such a comprehensive pack-
age, the COOLS trial promises to collect evidence and
information necessary for bridging the gap from discov-
ery to clinical application of FV-guided surgery into an
oral cancer solution for patients worldwide.
The COOLS trial is a large-scale study - large number
of patients, types of health professional specialties, and
geographically widespread institutions. The site estab-
lishment, personal training to standardize the protocol
including the use of study device, and quality assurance
are critical components to the success of the trial. To
ensure the quality of the trial, a multidisciplinary trial
coordinating centre has been developed to monitor the
trial operation and a web-based database application has
been created to facilitate the data, images, and sample
flow. A data safety monitoring board and a steering
committee have been formed to oversee the trial. Addi-
tionally, a central pathology review committee (chaired
by KWB) has been formed to document and review all
the margin pathology of the surgical samples and the
adjudication of the endpoint based on the pathology of
the follow-up biopsy.
At the time of writing, September 2011, 69 patients
have been enrolled from 4 sites. It is anticipated that
recruitment will be completed in August, 2013. Follow-
up will be completed two years later with results avail-
able by 2015.
This trial represents a pan-Canadian partnership of
sites and investigators/surgeons and is the first rando-
mized trial of the pan-Canadian Network for Oral Can-
cer Control or PanCanNOC. The network, serving as
the machinery for future research idea/projects, is com-
mitted to rigorously evaluating interventions in the pre-
vention and treatment of oral cancer.
Publication and reporting date
Expect late 2015 or early 2016.
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